Miniaturized Surgical Robotic Instruments Expand the Possibilities of Surgical Interventions

Food and Healthcare Press Releases Wednesday December 6, 2017 09:35
CALCI, Italy--6 Dec--PRNewswire/InfoQuest
  • MMI S.r.l. Unveils World's Smallest Robotic Wrist

Medical Microinstruments S.r.l. (MMI), a developer of novel robotic solutions for unmet medical needs, today reveals its robotic platform specifically designed for open microsurgery. The platform allows the surgeon to control two tiny articulated microinstruments that simplify reconstruction procedures after traumatic injuries as well as after tumor removal in soft tissue and bones, and offers the potential for improved surgical success rates and patient outcomes.

(Logo: http://mma.prnewswire.com/media/614046/MMI_Srl_Logo.jpg )
(Photo: http://mma.prnewswire.com/media/614047/MMI_Srl_Robotic_Wrist.jpg )
Video - https://www.youtube.com/watch?v=CTg262fMap0

MMI's instruments are equipped with the smallest articulated wrist having a 3-millimeter outer diameter and tips just 150 micron in width. The wrist is the key to performing robotic microsurgery in real clinical settings and allows easy manipulation of small sutures, from 9-0 to 12-0 in size.

"Thanks to the use of advanced materials and novel microfabrication processes, we have designed the smallest articulated wrist to provide microsurgeons unique instrument dexterity and robotic precision," said Massimiliano Simi, Co-founder and VP R&D.

The surgeon operates the microinstruments while sitting at the surgical bedside and looking through the operating microscope. MMI's robotic platform captures surgeon's hand movements and a scaled-down motion is imposed on the microinstruments.

"We have developed this groundbreaking technology together with microsurgeons from the product's conception and the positive feedback and response that we've received along the way has really been overwhelming and led us to believe that we are on the right track in developing a robot by and for microsurgeons," said Hannah Teichmann, Co-founder and VP Clinical.

Prof. Marco Innocenti, Chief of Plastic and Reconstructive Microsurgery at Careggi University Hospital in Florence and MMI's Clinical Advisor, who has presented preclinical work with MMI's robot at 9th Congress of World Society for Reconstructive Microsurgery in Seoul, including 0.35mm arterial robotic anastomosis, remarked:

"In my opinion, the MMI robotic platform will push the frontier of microsurgery forward and beyond the capabilities of the human hand, thus allowing more surgeons to perform more complex procedures but also enabling supermicrosurgery, such as lymph reconstruction, for the more expert ones."

MMI's President and Co-founder, Giuseppe Maria Prisco, estimates the potential annual market opportunity to be in the order of $2.5 billion.
Related links:
http://www.mmimicro.com
Watch the company video on http://www.mmimicro.com/mmi-video
About:

Medical Microinstruments S.r.l. (MMI), founded in 2015, is based in Calci (PI), Italy. The company's mission is to help more surgeons around the world to offer more advanced procedures, while reducing costs for patients, hospitals and for society at large.

Contact:
Vanya Petrova
Relationship Manager
vanya.petrova@mmimicro.com
+39-348-5441025
Source: MMI Srl

Latest Press Release

Israel Ministry of Health Includes INSIGHTEC#s Focused Ultrasound Treatment for Medication-Refractory Essential Tremor as Part of Covered Health Services

INSIGHTEC(R), a commercial-stage medical technology company revolutionizing surgery with incisionless MR-guided focused ultrasound (MRgFUS) announced today that the Neuravive focused ultrasound treatment will be a covered service for essential tremor...

The ImplantCenter Marks a New Era in the Hungarian Private Dental Service

The ImplantCenter has recently opened the brand-new operating room suited for more complex treatments. This comes alongside numerous additions such as the launch of the four cosy apartments to rest after treatments at the clinic and an implant education...

Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Merck and Pfizer Inc. (NYSE: PFE) today announced results from the Phase III JAVELIN Lung 200 trial comparing avelumab* to docetaxel in patients with unresectable, recurrent or metastatic non-small cell lung cancer (NSCLC) whose disease progressed after...

PharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics for Use in Drug Conjugates

PharmaMar (MCE: PHM) has announced today the signing of an exclusive licensing agreement with Seattle Genetics Inc. (SGEN: NASDAQ GS) under which Seattle Genetics receives exclusive worldwide rights to certain PharmaMar proprietary molecules for the...

After multiple failed procedures at other medical institutions, Colorado man successfully treated for Atrial Fibrillation at Texas Cardiac Arrhythmia Institute at St. David#s Medical Center

"I was thinking I was on top of the world," Wiseman said. "I was keeping myself in shape. I was taking care of myself mentally and physically. My relationship was solid." Then, during a routine medical exam while serving in the military in California,...

Related Topics